Silver Mines Ltd (ASX: SVL) is progressing its Bowdens silver project in the central west region of New South Wales, and expects to release its definitive feasibility study on the project imminently.

The analyst team at Morgans has run the ruler over the project and has come up with a very bullish share price target on Silver Mines shares, which we’ll get to shortly.

First, let’s have a look at why Morgans like the company so much.

Large silver project progressing toward development

Morgans said Silver Mines’ Bowdens project is Australia’s largest undeveloped silver resource and one of the largest globally.

The deposit also remains open beyond the current mining plan, “leaving room for reserve growth, mine life extension and underground potential”.

Morgans notes that direct silver exposure is rare among ASX miners, and in this case, “with silver contributing ~86% of life-of-mine revenue, Bowdens is one of the purest ways to gain leverage to rising silver prices through an advanced Australian development asset”.

The broker has modelled free cash flow of $1.63 billion over the life of the mine, and added, “we expect the upcoming Definitive Feasibility Study (DFS) to further refine the development pathway and potentially unlock additional value through updated pricing assumptions, optimisation initiatives and mine life extensions”.

They added:

We forecast first production in FY30, providing sufficient time for completion of the revised approvals process, project financing and construction. Following multiple engineering studies, metallurgical programmes and optimisation work, we consider Bowdens a technically mature development asset, leaving permitting and financing as the principal remaining milestones.

Shares looking cheap

Morgans has a 40 cent per share price target on Silver Mines, compared to the current price of 12.5 cents per share.

The broker said that the market, “continues to undervalue Bowdens’ combination of scale, technical maturity and leverage to a structurally improving silver market”.

They added:

While permitting remains the dominant risk, we believe this is increasingly offset by a more clearly defined approvals pathway, an advanced stage of project development, and multiple near term catalysts capable of reducing the regulatory discount currently reflected in the share price. Our thesis rests on what we view as an increasingly compelling asymmetry in Bowdens’ risk-reward profile, underpinned by exceptional leverage to a strengthening silver price, a technically mature development plan and a more clearly defined permitting pathway.

They added that their valuation only reflects a portion of the company’s broader options including further open pit cutbacks and potential resource growth.

Silver Mines is currently valued at $277.42 million.

The post This ASX silver mine developer could more than triple in value: Broker appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Netwealth, Silver Mines, and Qantas shares

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Caravel Minerals Ltd (ASX: CVV) have improved more than 39% over the past year, but they’re still trading well off their highs over the period.

But the analyst team at Shaw and Partners has recently initiated coverage on the ASX copper stock and believes shareholders should persist, predicting serious share price upside for the company.

Major copper project in development

So what does Caravel do? The company is currently finalising the definitive feasibility study for its Caravel copper project 150km northeast of Perth.

Shaw and Partners said in its recent research report that Caravel was one of the largest undeveloped copper resources globally.

They added:

The project is a large-scale, low-cost operation that will utilise bulk mining and automation to drive strong unit cost efficiencies, supported by its proximity to Perth, only 150km away. With a Tier-1 resource, progressing permitting and emerging strategic funding interest, Caravel is well positioned to develop a globally significant copper operation leveraged to ongoing structural demand growth from electrification, EVs and AI.

Shaw and Partners said a key advantage for the project was its proximity to established infrastructure which was unusual for projects of this size.

They added:

Located within trucking distance of Perth and connected to existing sealed roads, power infrastructure and skilled labour pools, the project avoids many of the logistical challenges faced by more remote copper developments. This infrastructure access significantly lowers capital intensity and operating risk relative to comparable greenfield projects.

Shaw and Partners said Caravel was progressing funding options while the definitive feasibility study was being finalised, “with the project’s scale and long mine life lending itself to a diversified capital stack”.

They added:

Caravel will pursue a mix of project debt, strategic investment and potential offtake-linked financing, to minimise dilution while providing the balance sheet required for construction. Strong interest from potential strategic partners and lenders, highlighted by the Adani non-binding MoU, reflects growing global demand for secure copper supply. This positioning enables Caravel to assemble a robust funding structure as development decisions approach.

Shaw and Partners said the growing demand for copper supported the reasons to buy ito the stock.

They said rapid growth in renewable energy, the electrification of transport and, “the rising power intensity of AI-driven data centres are expected to drive sustained copper consumption over the short, medium and long-term”.

The project also had significant precious metal and molybdenum by-products, Shaw and Partners said.

The broker has a $1.15 share price target on Caravel shares, which would be a 400% gain from the current share price of 23 cents.

Caravel is valued at $128.5 million.

The post Could this ASX copper share really rise 400%? appeared first on The Motley Fool Australia.

More reading

• This ASX silver mine developer could more than triple in value: Broker
• Mesoblast shares: Q4 earnings top projections
• Australia may sign a nuclear deal with India this week. What does that mean for Boss Energy shares?
• Ingenia Communities Group shares paused pending announcement
• Which is the best buy, Coles shares or Wesfarmers shares?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Mesoblast Ltd (ASX: MSB) share price is in focus today after the company reported fourth-quarter net revenue of US$36 million, boosting full-year revenue to US$115 million for the period ended 30 June 2026.

What did Mesoblast report?

• Fourth quarter net revenue: US$36 million
• Full-year net revenue: US$115 million
• Ryoncil^® uptake exceeded initial projections
• Strong capital position and funding for operations

What else do investors need to know?

Ryoncil^® is the first mesenchymal stromal cell (MSC) product approved by the US FDA for any indication and remains the only FDA-approved option for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD). This achievement has positioned Mesoblast as a leading developer of allogeneic cellular medicines targeting severe inflammatory diseases.

The company’s manufacturing capabilities continue to deliver industrial-scale, off-the-shelf cellular medicines. Mesoblast also has an extensive intellectual property portfolio, with patents that provide commercial protection through to at least 2044 in key markets.

What’s next for Mesoblast?

Looking ahead, Mesoblast expects continued revenue growth, supported by momentum across major US paediatric centres. The company’s robust capital base and new five-year facility are intended to support further strategic initiatives, including label extensions and new blockbuster product launches.

Mesoblast is advancing its Ryoncil^® therapy for additional inflammatory diseases, such as SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, while its rexlemestrocel-L platform targets heart failure and chronic low back pain.

Mesoblast share price snapshot

Over the past 12 months, Mesoblast shares have risen 27%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 2% over the same period.

View Original Announcement

The post Mesoblast shares: Q4 earnings top projections appeared first on The Motley Fool Australia.

More reading

• Ingenia Communities Group shares paused pending announcement
• Why brokers think Zip shares could soar 50% or more in FY27
• NEXTDC boosts funding with $2.3 billion senior debt facility upsize
• ASX 200 shares vs. US stocks in FY26
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.